COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY

被引：0
|
作者：
Taylor, D. C. [1 ]
Ozer-Deniz, S. [1 ]
Hill, G. [1 ]
Skornicki, M. [1 ]
Danel, A. [2 ]
Kunz, E. [3 ]
机构：
[1] I3 Innovus, Medford, MA USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen Europe GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71963-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A264
页数：2
相关论文
共 50 条
  • [41] Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study)
    Wolff, Thomas
    Schulz, Holger
    Losem, Christoph
    Reichert, Dietmar
    Hurtz, Hans-Juergen
    Sandner, Reiner
    Harde, Johanna
    Grebhardt, Sina
    Potthoff, Karin
    Mueller, Udo
    Fietz, Thomas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (02) : 174 - 181
  • [42] Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin’s lymphoma
    Wendy J. Langeberg
    Conchitina C. Siozon
    John H. Page
    P. K. Morrow
    Victoria M. Chia
    Supportive Care in Cancer, 2014, 22 : 2167 - 2175
  • [43] Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma
    Langeberg, Wendy J.
    Siozon, Conchitina C.
    Page, John H.
    Morrow, P. K.
    Chia, Victoria M.
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2167 - 2175
  • [44] A cost-effectiveness analysis of primary prophylaxis (PP) versus secondary prophylaxis (SP) with biosimilar myeloid growth factors (MGFs) for preventing chemotherapy-induced febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients at intermediate risk.
    Lyman, Gary H.
    Mezzio, Dylan
    Li, Edward C.
    Campbell, Kim
    Balu, Sanjeev
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (27)
  • [45] Primary prophylaxis of febrile neutropenia with pegfilgrastim is cost-effective compared with secondary prophylaxis for women with early-stage breast cancer receiving chemotherapy
    Ramsey, S. D.
    Liu, Z.
    Boer, R.
    Malin, J. L.
    Sullivan, S. D.
    Doan, Q., V
    Dubois, R. W.
    Lyman, G. H.
    VALUE IN HEALTH, 2007, 10 (03) : A125 - A126
  • [46] COST-EFFECTIVENESS OF PROPHYLAXIS TREATMENT STRATEGIES FOR FEBRILE NEUTROPENIA IN RECURRENT OVARIAN CANCER PATIENTS
    Fust, K.
    Li, X.
    Maschio, M.
    Barron, R.
    Weinstein, M. C.
    Parthan, A.
    Walli-Attaei, M.
    Chandler, D. B.
    Lyman, G. H.
    VALUE IN HEALTH, 2013, 16 (03) : A140 - A140
  • [47] Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer
    Fust, Kelly
    Li, Xiaoyan
    Maschio, Michael
    Barron, Richard
    Weinstein, Milton C.
    Parthan, Anju
    Walli-Attaei, Marjan
    Chandler, David B.
    Lyman, Gary H.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (03) : 446 - 453
  • [48] Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma
    McBride, Ali
    Krendyukov, Andriy
    Mathieson, Nicola
    Campbell, Kim
    Balu, Sanjeev
    Natek, Maja
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (01) : 28 - 36
  • [49] Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study
    Jean Paul Salmon
    Martin Smakal
    Charisios Karanikiotis
    Marek Z. Wojtukiewicz
    Yohann Omnes
    Lucy DeCosta
    Sally Wetten
    James O’Kelly
    Supportive Care in Cancer, 2019, 27 : 1449 - 1457
  • [50] Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer
    Yu, Joanne L.
    Chan, Kelvin
    Kurin, Michael
    Pasetka, Mark
    Kiss, Alex
    Sridhar, Srikala S.
    Warner, Ellen
    BREAST JOURNAL, 2015, 21 (06): : 658 - 664
12345